China Aoxing Pharmaceutical Company received SFDA approval to begin a clinical trial of Tilidine/Naloxone capsules, a narcotic drug for moderate to severe pain. The drug is given to alleviate cancer and post-surgical pain. China Aoxing plans to begin the clinical trial by the end of this year, and expects to receive final approval of the drug in 2011. As a Class III New Medicine, it will be given at least three years of market exclusivity protection following SFDA approval. More details...

Stock Symbol: (OTCBB: CAXG)